Loading
Life sciences · Journal article
International Health Sciences Review · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Localized prostate cancer is characterized by marked biological heterogeneity, creating a therapeutic dilemma in which the reduction of progression and metastatic risk must be weighed against treatment-related morbidity and long-term quality of life. This narrative review critically compares active surveillance with radical prostatectomy and radiotherapy in men with localized disease, emphasizing oncological outcomes, selection criteria, functional consequences, and shared decision-making. A structured literature search was conducted in 2026 using PubMed/MEDLINE and current European Association of Urology and American Urological Association/American Society for Radiation Oncology guidance. Randomized trials, long-term active-surveillance cohorts, prospective patient-reported outcome studies, systematic reviews, and contemporary observational evidence were prioritized. Long-term randomized evidence shows very low prostate-cancer-specific mortality across monitoring, surgery, and radiotherapy in predominantly PSA-detected localized disease, but conservative management is associated with more progression and metastases. Modern protocol-directed active surveillance, however, differs from older PSA-triggered monitoring by incorporating magnetic resonance imaging, repeat biopsy, and risk reclassification, and contemporary cohorts report low 10-year rates of metastasis and prostate-cancer mortality in appropriately selected patients. Quality-of-life profiles differ substantially by strategy: radical prostatectomy produces the greatest early and persistent burden of urinary incontinence and sexual dysfunction, whereas radiotherapy more often causes bowel symptoms and irritative urinary effects, with additional hormonal toxicity when androgen-deprivation therapy is used. Active surveillance preserves baseline function initially but requires repeated testing and carries the psychological and clinical burden of living with untreated cancer. The optimal approach is therefore risk-adapted rather than uniformly conservative or radical. Active surveillance is the standard strategy for most men with low-risk disease and selected favorable intermediate-risk disease, while radical treatment remains appropriate when tumor biology, extent, life expectancy, patient preference, or evidence of progression shifts the balance toward definitive local control.